Siegel RL, Miller KD, Jemal A, Cancer statistics (2019) CA: a cancer journal for clinicians. 69: 7–34

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. Cancer J Clin 71:209–249

Article  Google Scholar 

Goebell PJ, Raina R, Chen S, Rege S, Shah R, Grossman JP, Waldeck AR (2024) Real-world treatment of metastatic hormone-sensitive prostate cancer in the USA, Europe and Asia. Future Oncol (London England) 20:903–918

Article  CAS  Google Scholar 

Cornford P, Tilki D, van den Bergh RCN et al (2024) EAU Guidelines on Prostate Cancer. Edn. presented at the EAU Annual Congress Paris 2024: ISBN 978-94-92671-23-3

Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, Özgüroğlu M, Ye D, Feyerabend S, Protheroe A, Sulur G, Luna Y, Li S, Mundle S, Chi KN (2019) Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol 20:686–700

Article  CAS  PubMed  Google Scholar 

Kyriakopoulos CE, Chen Y-H, Carducci MA, Liu G, Jarrard DF, Hahn NM, Shevrin DH, Dreicer R, Hussain M, Eisenberger M, Kohli M, Plimack ER, Vogelzang NJ, Picus J, Cooney MM, Garcia JA, DiPaola RS, Sweeney CJ (2018) Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. J Clin oncology: official J Am Soc Clin Oncol 36:1080–1087

Article  CAS  Google Scholar 

Wenzel M, Würnschimmel C, Nocera L, Collà Ruvolo C, Tian Z, Shariat SF, Saad F, Briganti A, Tilki D, Graefen M, Kluth LA, Roos FC, Mandel P, Chun FKH, Karakiewicz PI (2022) Overall Survival After Systemic Treatment in High-volume Versus Low-volume Metastatic Hormone-sensitive Prostate Cancer: Systematic Review and Network Meta-analysis. Eur Urol focus 8:399–408

Article  PubMed  Google Scholar 

Brierley J, Gospodarowicz MK, Wittekind C, Eds (2017) TNM classification of malignant tumours; John Wiley & Sons Inc; Wiley Blackwell: Chichester, West Sussex, UK, Hoboken, NJ, Chichester, West Sussex

Gandaglia G, Karakiewicz PI, Briganti A, Passoni NM, Schiffmann J, Trudeau V, Graefen M, Montorsi F, Sun M (2015) Impact of the Site of Metastases on Survival in Patients with Metastatic Prostate Cancer. Eur Urol 68:325–334

Article  PubMed  Google Scholar 

Pond GR, Sonpavde G, Wit R (2014) The prognostic importance of metastatic site in men with metastatic castration-resistant prostate cancer. Eur Urol 65:3–6EisenbergerM.A.Tannock, I.F.; Armstrong, A.J

Article  PubMed  Google Scholar 

Deutsche Krebsgesellschaft D, Krebshilfe AWMF (2024) (Leitlinienprogramm Onkologie). S3-Leitlinie Früherkennung, Diagnose und Therapie des Prostatakarzinoms: Version 6.1

Wenzel M, Hoeh B, Humke C, Cano Garcia C, Siech C, Steuber T, Graefen M, Traumann M, Kluth L, Chun FKH, Mandel P (2024) Androgen receptor pathway inhibitors vs. docetaxel chemotherapy for metastatic hormone-sensitive and first-line castration resistant prostate cancer. World J Urol 43:51

Article  PubMed  PubMed Central  Google Scholar 

Wenzel M, Steuber T, Siech C, Kriegmair M, Hoeh B, Tilki D, Merseburger AS, Chun FKH, Mandel P (2025) Ultralow Prostate-specific Antigen Nadir After Apalutamide: Outcomes in Synchronous Versus Metachronous Metastatic Hormone-sensitive Prostate Cancer. Eur Urol open Sci 77:19–22

Article  PubMed  PubMed Central  Google Scholar 

Wenzel M, Preisser F, Hoeh B, Schroeder M, Würnschimmel C, Steuber T, Heinzer H, Banek S, Ahrens M, Becker A, Karakiewicz PI, Chun FKH, Kluth LA, Mandel P (2021) Impact of Time to Castration Resistance on Survival in Metastatic Hormone Sensitive Prostate Cancer Patients in the Era of Combination Therapies. Front Oncol 11:659135

Article  PubMed  PubMed Central  Google Scholar 

Elewaily MI, Campione M, Hassan MA, Anpalakhan S, Atsumi N, Smalley B, Ashraf A, Gale J, Maniam A, Banna GL (2024) Prognostic factors and treatment choice for stage IV, low-volume metastasis hormone-sensitive prostate cancer: cross-sectional study of real-world data. Ther Adv Urol 16:17562872241297579

Article  CAS  PubMed  PubMed Central  Google Scholar 

Miyake H, Matsushita Y, Watanabe H, Tamura K, Motoyama D, Ito T, Sugiyama T, Otsuka A (2019) Prognostic Significance of Time to Castration Resistance in Patients With Metastatic Castration-sensitive Prostate Cancer. Anticancer Res 39:1391–1396

Article  PubMed  Google Scholar 

Wang Z-P, Chen J-R, Zhao J-G, Zhu S, Zhang X-M, Liang J-Y, He B, Ni Y-C, Sun G-X, Shen P-F, Zeng H (2023) Regional location of lymph node metastases predicts survival in patients with de novo metastatic prostate cancer. Asian J Androl 25:462–467

Article  PubMed  PubMed Central  Google Scholar 

Halabi S, Kelly WK, Ma H, Zhou H, Solomon NC, Fizazi K, Tangen CM, Rosenthal M, Petrylak DP, Hussain M, Vogelzang NJ, Thompson IM, Chi KN, Bono J (2016) Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer. JCO 34:1652–1659ArmstrongA.J.Eisenberger, M.A.; Fandi, A.; Li, S.; Araujo, J.C.; Logothetis, C.J.; Quinn, D.I.; Morris, M.J.; Higano, C.S.; Tannock, I.F.; Small, E.J.

Article  CAS  Google Scholar 

Paffenholz P, Roesch MC (2024) Medikamentöse Tumortherapie des mHSPC: Double- oder Tripletherapie: wer, wann und wie? Aktuelle Urologie 55:116–122

Article  PubMed  Google Scholar 

Hamid AA, Sayegh N, Tombal B, Hussain M, Sweeney CJ, Graff JN, Agarwal N (2023) Metastatic Hormone-Sensitive Prostate Cancer: Toward an Era of Adaptive and Personalized Treatment. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 43, e390166